Reid Robison, live as he presents the Company’s model for scaling access to psychedelic medicine through a multi-state, U.S. Join Novamind’s Chief Medical Officer and Director, Dr. (CSE: NM | OTCQB: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the Life Sciences Investor Forum, taking place virtually on Thursday, September 16 at 12:00 PM EST. 15, 2021 (GLOBE NEWSWIRE) - Novamind Inc.
Novamind logo update#
The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.TORONTO, Sept. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information.
Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. This news release contains forward-looking statements. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites.
It's an exciting opportunity to unify our current and future assets under one unique identity that will become a trusted and recognized name for innovative mental healthcare in communities across the U.S." Yaron Conforti, CEO and Director, commented: "The new logo, rebrand and website reflects our rapid evolution over the last year. Taking inspiration from the revitalized logo, the website will provide an accessible digital entry point to Novamind's world-class care and clinical research offerings. The Company is also improving its website to scale alongside its growth strategy and better serve diverse audiences with enhanced content and tools. The logo reveal kicks off the multi-phase rebrand of the Company's network of clinics and research sites, expected to be complete in 2022. The open doorway at the centre of the logo, working in conjunction with the radiating lines, is an invitation towards an improved way of life-one where taking care of mental health is a priority. The logo integrates and flows across all digital and physical properties, and represents Novamind's core beliefs in hope, healing and transformation. Novamind's new logo is now live on its corporate website and social media platforms.
0 kommentar(er)
